



Supplementary Figure 2. Change scores in patient-reported outcomes of (A) GH VAS, (B) HAQ-DI, and (C) EQ-5D in the bDMARD and JAKi groups (PP analysis). Bar presents the mean with a 95% confidence interval of change scores in patient-reported outcomes. GH VAS, Global Health assessment using Visual Analogue Scale; HAQ-DI, health assessment questionnaire-disability index; EQ-5D, EuroQol-5 dimension; bDMARD, biologic disease-modifying antirheumatic drug; JAKi, Janus kinase inhibitors; PP: per protocol.